Ovid Therapeutics Files 8-K

TL;DR

Ovid Therapeutics filed an 8-K on 6/25/25 for 'Other Events' - check the details.

AI Summary

Ovid Therapeutics Inc. filed an 8-K on June 25, 2025, reporting an event under "Other Events." The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices located at 441 Ninth Avenue, 14th Floor, New York, NY 10001. The report was filed as of June 25, 2025.

Why It Matters

This filing indicates a material event has occurred for Ovid Therapeutics, requiring public disclosure. Investors should review the details of the 'Other Events' to understand the implications for the company.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not inherently indicate significant risk without further context on the 'Other Events'.

Key Numbers

• 001-38085 — SEC File Number (Identifies the company's filing with the SEC.)
• 46-5270895 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant
• June 25, 2025 (date) — Date of Report
• 441 Ninth Avenue, 14th Floor, New York, New York 10001 (location) — Principal Executive Offices
• Delaware (location) — State of Incorporation

FAQ

From the Filing

0001628280-25-032959.txt : 20250625 0001628280-25-032959.hdr.sgml : 20250625 20250625082225 ACCESSION NUMBER: 0001628280-25-032959 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250625 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250625 DATE AS OF CHANGE: 20250625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 251071096 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 8-K 1 ovid-20250625.htm 8-K ovid-20250625 0001636651 false 0001636651 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       441 Ninth Avenue , 14th Floor New York , New York 10001 (Address of Principal Executive Offices)    (Zip Code) Registrant’s Telephone Number, Including Area Code: 646 - 661-7661 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   OVID   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Item 8.01.    Other Events. On June 23, 2025 (the “First Amendment Effective Date”), Ovid Therapeutics Inc. (the “Company”) entered into Amendment No. 1 to Exclusive Patent License Agreement (the “First Amendment”) with Immedica Pharma, AB (“Immedica”), which amended the Exclusive Patent License Agreement between the Company and Marinus Pharmaceuticals, Inc. (“Marinus”), a wholly-owned subsidiary of Immedica since February 2025, dated March 1, 2022 (the “Original Agreement”). Pursuant to the First Amendment, Immedica purchased the ongoing royalty obligations under the Original Agreement for $7.0 million in cash, payable within 10 business days following the First Amendment Effective Date. Under the Original Agreement, the Company granted Marinus an exclusive,